Xcout Intel
PhaseV
PhaseV uses causal machine learning and generative AI to optimize clinical trial designs and improve drug development processes.
Subscribe to see PhaseV’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
PhaseV at a glance
PhaseV is a healthtech company headquartered in Israel, founded in 2023. It has raised at least $65M across the 2 funding rounds on record. Its most recent funding round, Series A, raised $50M in May 2025. Xcout tracks 3 named people at PhaseV, including Raviv Pryluk, PhD (CEO, Co-Founder). Xcout recorded 16 job postings from PhaseV in the last 90 days.
PhaseV leadership
- Raviv Pryluk, PhDCEO, Co-Founder
- Elad Berkman, MScCTO, Co-Founder
- Dan Goldstaub, PhDScientific Co-Founder
PhaseV funding rounds
At least $65M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $50M | 2 named | |
| — | $15M | 2 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Hiring at PhaseV
Xcout recorded 16 job postings from PhaseV in the last 90 days, from a hiring record Xcout has kept since June 2026.
The weekly hiring trend, the roles and locations behind it — see PhaseV's hiring signals →
Investors
PhaseV competitors
A few of PhaseV's closest competitors — see the full list of competitors and alternatives →
ArcaScience is a pharmaceutical artificial intelligence company headquartered in Paris, France, that develops an advanced benefit-risk decision engine and drug safety platforms.
Aira Health is a biotechnology research company based in Boston, Massachusetts, that provides a unified AI platform for clinical trial design and protocol development.
SwitchPoint Bio Holding, Inc. operates a platform that combines precision epigenomics and artificial intelligence to analyze cellular biology from blood samples. The company provides biomarker discovery, patient stratification, and treatment response mechanism readouts to support drug development and clinical research.
Novadiscovery provides a collaborative clinical trial simulation platform called jinkō that uses disease models and digital patients to predict clinical outcomes. The company serves pharmaceutical and life sciences organizations by optimizing trial design, reducing risks to human subjects, and accelerating drug development from discovery to market access.
Nova In Silico provides a collaborative clinical trial simulation platform called jinkō, which uses disease models and virtual patient populations to predict clinical outcomes. The company serves pharmaceutical and biotech organizations by helping them optimize trial design, reduce risks to human subjects, and accelerate drug development from discovery to market access.
Get PhaseV's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about PhaseV? Suggest a correction
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on PhaseV in Xcout Intel
- 3 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- Weekly hiring history and the mix of roles behind it
- The full competitor set, tracking, exports and API access